View Cart (0 items)

Court Affirms ADHD Drug Patent Ruling

April 26, 2010
/ Print / Reprints /
| Share More
/ Text Size+
Watson Pharmaceuticals Inc. said that an appeals court affirmed that a disputed patent on Johnson & Johnson''s attention deficit drug Concerta is invalid, the Associated Press reports. In March 2009, the U.S. District Court in Wilmington, Del., ruled that the primary patent on J&J''s drug was invalid and that Watson''s planned generic version doesn''t infringe on the patent. The pill is the fifth-best-selling prescription drug for Johnson & Johnson, with global sales of $1.33 billion last year. On Monday, the U.S. Court of Appeals for the Federal Circuit Court affirmed the lower court''s ruling. J&J affirmed the appeals court decision. Watson said its generic version of Concerta has yet to be approved by the Food and Drug Administration.
You must login or register in order to post a comment.